Related references
Note: Only part of the references are listed.Cannabidiol drug interaction considerations for prescribers and pharmacists
Myfanwy Graham et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2022)
Reduction in Tamoxifen Metabolites Endoxifen and N-desmethyltamoxifen With Chronic Administration of Low Dose Cannabidiol: A CYP3A4 and CYP2D6 Drug Interaction
Vikas Parihar et al.
JOURNAL OF PHARMACY PRACTICE (2022)
Five-Year Adjuvant Endocrine Therapy Adherence Trajectories Among Women With Breast Cancer: A Nationwide French Study Using Administrative Data
Gregory Lailler et al.
CLINICAL BREAST CANCER (2021)
Clinical CYP2D6 Genotyping to Personalize Adjuvant Tamoxifen Treatment in ER-Positive Breast Cancer Patients: Current Status of a Controversy
Tessa A. M. Mulder et al.
CANCERS (2021)
Medical cannabis or cannabinoids for chronic non-cancer and cancer related pain: a systematic review and meta-analysis of randomised clinical trials
Li Wang et al.
BMJ-BRITISH MEDICAL JOURNAL (2021)
Cannabidiol Drugs Clinical Trial Outcomes and Adverse Effects
Christopher S. Pauli et al.
FRONTIERS IN PHARMACOLOGY (2020)
A survey of breast cancer patients’ use of cannabis before, during, and after treatment.
Marisa C. Weiss et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Cannabinoids and Cannabinoid Receptors: The Story so Far
Fred Shahbazi et al.
ISCIENCE (2020)
The Essential Medicinal Chemistry of Cannabidiol (CBD)
Kathryn M. Nelson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Impact of Curcumin (with or without Piperine) on the Pharmacokinetics of Tamoxifen
Koen G. A. M. Hussaarts et al.
CANCERS (2019)
Future Aspects for Cannabinoids in Breast Cancer Therapy
Terezia Kiskova et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
F. Cardoso et al.
ANNALS OF ONCOLOGY (2019)
Potential Adverse Drug Events and Drug-Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use
Joshua D. Brown et al.
JOURNAL OF CLINICAL MEDICINE (2019)
The pharmacokinetics and the pharmacodynamics of cannabinoids
Catherine J. Lucas et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients
Thomas Helland et al.
BREAST CANCER RESEARCH (2017)
An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies
Kerstin Iffland et al.
CANNABIS AND CANNABINOID RESEARCH (2017)
Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer
P. Saladores et al.
PHARMACOGENOMICS JOURNAL (2015)
Health-related quality of life, psychological distress, and adverse events in postmenopausal women with breast cancer who receive tamoxifen, exemestane, or anastrozole as adjuvant endocrine therapy: National Surgical Adjuvant Study of Breast Cancer 04 (N-SAS BC 04)
Hiroyuki Takei et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review
Caitlin C. Murphy et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Effects of CYP Induction by Rifampicin on Tamoxifen Exposure
L. Binkhorst et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Cannabis, a complex plant: different compounds and different effects on individuals
Zerrin Atakan
THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY (2012)
Health-related quality of life and psychological distress of breast cancer patients after surgery during a phase III randomized trial comparing continuation of tamoxifen with switching to anastrozole after adjuvant tamoxifen for 1-4 years: N-SAS BC 03
Shozo Ohsumi et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Tamoxifen Metabolite Concentrations, CYP2D6 Genotype, and Breast Cancer Outcomes
L. Madlensky et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Cannabidiol, a Major Phytocannabinoid, As a Potent Atypical Inhibitor for CYP2D6
Satoshi Yamaori et al.
DRUG METABOLISM AND DISPOSITION (2011)
Quantification of tamoxifen and three of its phase-I metabolites in human plasma by liquid chromatography/triple-quadrupole mass spectrometry
Lisette Binkhorst et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2011)
Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer
Cynthia Owusu et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Quality of life of postmenopausal women in the ATAC (Arimidex, tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer
David Cella et al.
BREAST CANCER RESEARCH AND TREATMENT (2006)
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Share Paper
